33000-64-5

Basic information

• Product Name: 1-Propanone, 2-bromo-1-(4-chlorophenyl)-2-methyl-
• CAS NO: 33000-64-5
• Molecular Formula: C10H10BrClO
• Molecular Weight: 261.546
• Mol File: 33000-64-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1-Propanone, 2-bromo-1-(4-chlorophenyl)-2-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propanone, 2-bromo-1-(4-chlorophenyl)-2-methyl-(33000-64-5)
• EPA Substance Registry System: 1-Propanone, 2-bromo-1-(4-chlorophenyl)-2-methyl-(33000-64-5)

Safety Data

• Hazardous Substances Data: 33000-64-5(Hazardous Substances Data)

Usage

Type of compound

Synthetic psychoactive drug

Classification

Cathinone class of stimulants

Structural relation

Related to other synthetic cathinones such as MDPV and alpha-PVP

Mechanism of action

Potent and selective dopamine reuptake inhibitor

Recreational effects

Increased energy, enhanced mood, and euphoria

Negative side effects and health risks

Range of potential negative side effects and health risks

Legal status

Regulated or banned in several countries due to concerns about abuse potential and health hazards.

Upstream product

• 13206-46-7 2-bromo-2-methylpropanal 
• 108-90-7 chlorobenzene 
• 20769-85-1 2-bromoisobutyric acid bromide 
• 18713-58-1 1-(4-chlorophenyl)-2-methylpropan-1-one 

Downstream Products

• 118362-76-8 3-(4-chlorophenyl)-2,2-dimethyl-3-oxopropanenitrile 
• 18713-58-1 1-(4-chlorophenyl)-2-methylpropan-1-one 
• 71867-96-4 1-(4-chlorophenyl)-2-hydroxy-2-methylpropan-1-one 
• 88283-69-6 2-(4-chlorophenyl)-2-[2-(p-chlorophenoxy)-prop-2-yl]-oxirane 
• 102846-61-7 4-chlorophenyl 2-(4-methoximino-methyl-phenoxy)-2-propyl ketone 
• 46779-82-2 1-(4-chloro-phenyl)-2-imidazol-1-yl-2-methyl-propan-1-one 
• 88539-01-9 2-(4-Chloro-phenyl)-2-ethoxy-3,3-dimethyl-oxirane 
• 33000-65-6 2-(4-chloro-phenyl)-2-methoxy-3,3-dimethyl-oxirane 
• 64220-40-2 5-chloro-2-methyl-2,3-dihydro-1H-inden-1-one 

Relevant articles and documents

Discovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator

The recent approval of aducanumab for Alzheimer's disease has heightened the interest in therapies targeting the amyloid hypothesis. Our research has focused on identification of novel compounds to improve amyloid processing by modulating gamma secretase activity, thereby addressing a significant biological deficit known to plague the familial form of the disease. Herein, we describe the design, synthesis, and optimization of new gamma secretase modulators (GSMs) based on previously reported oxadiazine 1. Potency improvements with a focus on predicted and measured properties afforded high-quality compounds further differentiated via robust Aβ42 reductions in both rodents and nonhuman primates. Extensive preclinical profiling, efficacy studies, and safety studies resulted in the nomination of FRM-024, (+)-cis-5-(4-chlorophenyl)-6-cyclopropyl-3-(6-methoxy-5-(4-methyl-1H-imidazole-1-yl)pyridin-2-yl)-5,6-dihydro-4H-1,2,4-oxadiazine, as a GSM preclinical candidate for familial Alzheimer's disease.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

Substituted diazolylalkyl-carbinols, a process for their preparation and their use as antimycotic agents

The invention relates to compounds and their derivatives, said compounds being described herein as those of Formula (I). The compounds and compositions containing them are effective antimycotic agents and the invention includes methods for the use of said compounds and compositions.